Analysts turn bullish on SLS ahead of acute myeloid leukemia updates, JPMorgan and Stifel announcement fresh interest

Shares of SLS drew notable attention in trading after multiple sell-side actions and market chatter framed the next catalyst as a block of data tied to AML, or acute myeloid leukemia, a cancer affecting blood and bone marrow.

In the latest bullish revision cited by the market post, Alliance Global increased its price target on SLS to $35 from $25, a step described as implying nearly 200% upside from the level referenced in that analysis. The firm maintained a Buy rating.

The same post also said that JPMorgan “buys in,” indicating the investment bank’s stance or activity was turning more constructive ahead of the AML readout. Separately, it said Stifel boosted its bet, suggesting additional positive sentiment from another major brokerage.

While the post highlighted these changes, it did not provide full detail on what exactly the firm-level actions involved. It did not specify the size of JPMorgan’s position, whether Stifel’s “boost” reflected an updated target price, a rating change, or model adjustments, or the exact timing or form of the AML data release.

The market reaction underscores how biotech stocks often trade around discrete clinical milestones, particularly when investors are waiting for effectiveness or safety indicates from studies in specific disease settings. For SLS, the emphasis on AML suggests the company’s near-term investor narrative is likely anchored to new information that could clarify the potential for its pipeline in that indication.

JPMorgan’s involvement in the story is best read in the context of how large banks participate in research coverage and market-making activity that can influence sentiment, rather than as an indication of long-term fundamentals on its own. Stifel’s update points to a similar dynamic, with analysts frequently updating valuation scenarios as new clinical or preclinical evidence approaches.

Still, important questions remain unanswered based on the information provided in the post. It did not disclose what Alliance Global assumed in its nearly 200% upside framing, whether that target relied on particular endpoints, or how the anticipated AML update could change expectations for timelines, regulatory prospects, or competitive positioning.

Investors watching SLS next are likely to focus on whether the AML data delivers the kind of announcement that can justify higher valuation targets like $35, and whether additional analyst commentary converges on similar assumptions. Until the company provides further specifics or the full details of these brokerage actions are published, much of the near-term narrative remains centered on anticipation rather than confirmed trial outcomes.